Terlipressin Acetate Patent Expiration
Terlipressin Acetate is Used for improving kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. It was first introduced by Mallinckrodt Pharmaceuticals Ireland Ltd
Terlipressin Acetate Patents
Given below is the list of patents protecting Terlipressin Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Terlivaz | US10335452 | Method of treating patients with hepatorenal syndrome type 1 | Apr 05, 2037 | Mallinckrodt Ireland |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Terlipressin Acetate's patents.
Latest Legal Activities on Terlipressin Acetate's Patents
Given below is the list recent legal activities going on the following patents of Terlipressin Acetate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Jan, 2023 | US10335452 |
| Patent Issue Date Used in PTA Calculation Critical | 02 Jul, 2019 | US10335452 |
| Recordation of Patent Grant Mailed Critical | 02 Jul, 2019 | US10335452 |
| Email Notification Critical | 13 Jun, 2019 | US10335452 |
| Issue Notification Mailed Critical | 12 Jun, 2019 | US10335452 |
| Dispatch to FDC | 05 Jun, 2019 | US10335452 |
| Application Is Considered Ready for Issue Critical | 22 May, 2019 | US10335452 |
| Issue Fee Payment Verified Critical | 21 May, 2019 | US10335452 |
| Issue Fee Payment Received Critical | 21 May, 2019 | US10335452 |
| Electronic Review Critical | 25 Feb, 2019 | US10335452 |
Terlipressin Acetate's Family Patents
